Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$61.48
neg -0.86
-1.38%
Today's Range: 61.20 - 62.07 | MRK Avg Daily Volume: 11,206,000
Last Update: 01/17/17 - 4:00 PM EST
Volume: 10,586,085
YTD Performance: 5.89%
Open: $61.92
Previous Close: $62.34
52 Week Range: $47.97 - $65.46
Oustanding Shares: 2,757,137,517
Market Cap: 171,879,952,810
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 8 8 6
Moderate Buy 1 0 0 0
Hold 3 6 6 7
Moderate Sell 1 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.68 1.86 1.86 2.08
Latest Dividend: 0.47
Latest Dividend Yield: 3.02%
Dividend Ex-Date: 12/13/16
Price Earnings Ratio: 31.81
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
31.81 32.00 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.27% 23.06% 17.36%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.20 -0.06
Net Income -62.60 -0.30 -0.11
EPS -61.70 -0.20 -0.08
Earnings for MRK:
EBITDA 13.92B
Revenue 39.50B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $0.88 $0.93 $3.76 $3.83
Number of Analysts 8 2 10 10
High Estimate $0.93 $0.93 $3.82 $3.98
Low Estimate $0.84 $0.93 $3.72 $3.69
Prior Year $0.93 $0.89 $3.59 $3.76
Growth Rate (Year over Year) -5.51% 4.49% 4.85% 1.70%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

bullishMerck upgraded at Piper

Jan 12, 2017 | 7:21 AM EST
MRK was upgraded from Neutral to Overweight, Piper Jaffray said. $72 price target. Expect conditional approval for Keytruda by May.

bullishMerck upgraded at Morgan Stanley

Jan 12, 2017 | 7:06 AM EST
MRK was upgraded from Equal-weight to Overweight, Morgan Stanley said. $71 price target. Expect that immuno-oncology can accelerate growth.
RMPIA
By

Jim Cramer

 | Jan 11, 2017 | 2:31 PM EST
He's never really been a stock market guy anyway.
By

Jim Cramer

 | Jan 11, 2017 | 6:39 AM EST
The terror that the futures struck, rightly or wrongly, has disappeared.
RMPIA
By

Doug Kass

 | Jan 10, 2017 | 5:14 PM EST
"I don't feel Tuesday...Tuesday has no feel." --
RMPIA
By

Bret Jensen

 | Jan 10, 2017 | 10:00 AM EST
Animal health and oncology deal activity is heating up in 2017.
RMPIA
By

Doug Kass

 | Jan 9, 2017 | 4:17 PM EST
The U.S. dollar weakened -- now for about three days in a row. Crude oil dropped by $2.06 to under $52 a barrel. Gold rose by $11. Ag commodities: wheat up $0.04, corn up $0.15, soybeans up $0.10 and oats down $0.02. Lumber down $6.60. Bonds rallied, with yields about 4 basis points lower. The 2s/10s spread contracted by 2 basis points. Municipals were well bid (closed-end muni-bond funds were quite strong), along with taxables. Junk bonds were flat in price and yield. Blackstone/GSO Strategic Credit Fund (BGB) rose by another $0.04. Banks held firm, but brokerages and life insurance was lower. Autos unchanged. Energy got whacked with a two-beaner drop in oil. Old tech was mixed. But, Best Ideas short IBM (IBM)   tumbled by nearly $2 a share. Ag equipment -- the object of my disaffection -- were lower with both Deere (DE) and Caterpillar (CAT) weak. Jim "El Capitan" Cramer highlighted the bullish case for Caterpillar today.  Retail continues to be a land mine. Big pharma rallied led by Merck (MRK) and Eli Lilly (LLY) . Biotech was stronger -- plus 2% led by Allergan (AGN) (again!) and thanks to a high-profile M&A deal. Consumer staples suffered from Coca-Cola (KO) and Procter & Gamble (PG) research downgrades. I added to Campbell Soup (CPB) , however. (T)FANG, again popular -- continued so but far less than the strong Thursday-Friday period from last week. Here are some value-added contributions on our site today: 1. My dachshunds were partial to Jim "E l Capitan" Cramer's column that highlighted the pet/vet business. 2. Ben "Godlfinger" Cross on confidence. 3. Jeremy Lakosh on the
RMPIA
By

Jim Cramer

 | Jan 9, 2017 | 6:37 AM EST
You have to think that if these stocks were so high once, then it's likely they will be again.
RMPIA
By

David Katz

 | Jan 8, 2017 | 2:00 PM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

Jim Cramer

 | Jan 6, 2017 | 3:10 PM EST
Disney and Goldman are doing a lot of the heavy lifting.
Shares of PG area trading at new January highs this afternoon.  The stock is up over ...
Market slightly down across the board to start the holiday shortened trading week.  N...
This morning, Morgan Stanley reported solid results for Q4, ahead of estimates for both re...
See my Jan. 12, 2017 Real Money Pro article for details on my thought process regarding Ch...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.